The Law Offices of James Scott Farrin Prepares to Fight for Clients After Study Links Xeljanz/Xeljanz XR to Severe Cardiac Events, Pulmonary Embolisms The drug, approved in 2012 and prescribed to thousands of people, was linked to life-threatening and previously undisclosed side effects. News provided by Share this article Share this article DURHAM, N.C., May 20, 2021 /PRNewswire/ -- A thorough post-marketing study on the prescription drug Xeljanz has revealed a possible link to potentially fatal side effects that were never disclosed. Specifically, the study noted blood clotting issues including deep vein thrombosis (DVT) and pulmonary embolism (PE), along with severe cardiac events. Click here for more information on the study and on Xeljanz.